Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
IMV Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.000001 |
52 Week High | US$0.25 |
52 Week Low | US$0.000001 |
Beta | 0 |
11 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | -100.00% |
33 Year Change | -100.00% |
5 Year Change | -100.00% |
Change since IPO | -100.00% |
Recent News & Updates
Recent updates
IMV to cut ~33% workforce amid reorganization
Sep 15IMV receives Nasdaq non-compliance letter
Jul 08IMV names Jeremy Graff as chief scientific officer
Jun 09IMV's vaccine candidate potentially effective against COVID-19, shares up 16%
Dec 28IMV T cell therapy shows positive action in treatment-resistant ovarian cancer; shares up 5%
Dec 03IMV reports Q3 results
Nov 12Shareholder Returns
IMVI.F | US Biotechs | US Market | |
---|---|---|---|
7D | 0% | 0.1% | 0.06% |
1Y | -100.0% | 13.8% | 22.6% |
Return vs Industry: IMVI.F underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: IMVI.F underperformed the US Market which returned 22.2% over the past year.
Price Volatility
IMVI.F volatility | |
---|---|
IMVI.F Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 10.4% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.0% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IMVI.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine IMVI.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 63 | Andrew Hall | www.imv-inc.com |
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX, an immune-educating technology platform for treatment of solid and hematological cancers. The company’s lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer.
IMV Inc. Fundamentals Summary
IMVI.F fundamental statistics | |
---|---|
Market cap | US$11.00 |
Earnings (TTM) | -US$37.99m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs IMVI.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IMVI.F income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$23.28m |
Gross Profit | -US$23.28m |
Other Expenses | US$14.71m |
Earnings | -US$37.99m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did IMVI.F perform over the long term?
See historical performance and comparison